top of page

Cardiff Oncology CEO Mark Erlander discusses last week's data for the PLK1 inhibitor onvansertib in first-line RAS-mutated mCRC

  • blonca9
  • Dec 16, 2024
  • 1 min read

He describes the rationale for PLK1 inhibition and highlights the significance of the data, which will have an additional update next year. Plus, where Cardiff believes it can go beyond colorectal cancer with this asset.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

evaluate-logo-png_seeklogo-457165-2_edited.png

Evaluate is a trusted provider of forecasting and commercial intelligence to the pharmaceutical industry. With a combination of gold standard data sources and deep pharma expertise, Evaluate helps clients make the right portfolio decisions to drive growth.

Evaluate's solutions provide a complete, dynamic view of development risk and commercial return across the full clinical lifecycle, underpinned by consensus forecasts to 2032, pipelines, deals and more. A consulting and analytics team is on always hand to help clients address unique clinical and commercial challenges.

bottom of page